We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA OFFICIAL: AGENCY NOT INTERESTED IN COMPARATIVE TRIALS

FDA OFFICIAL: AGENCY NOT INTERESTED IN COMPARATIVE TRIALS

July 3, 2006

The FDA is rejecting the efforts of some healthcare groups to use head-to-head trials between different drug products as part of new drug applications, arguing that these tests are less efficient or effective than placebo-controlled tests, a high-ranking agency official says.

The FDA does not want comparative data from drug sponsors, Scott Gottlieb, the FDA's deputy commissioner for medical and scientific affairs, said at a recent conference. This pronouncement comes as the agency has seen an upswing in the number of drug sponsors that have submitted this type of data as part of their new drug applications.

While comparative studies are useful in some situations, such as cancer treatments, where using a placebo would be unethical because not treating the disease can lead to death, in most cases placebos are much more effective in demonstrating a product's effectiveness, Gottlieb said. It simply is too difficult, the agency believes, to discern benefits of a drug when it's compared with another similar treatment, as opposed to a placebo.

"We don't think [comparative] trials are very valuable," he said.

However, some healthcare and activist groups, including Consumers Union, the Pharmaceutical Care Management Association and the Alliance for Better Healthcare, a healthcare benefits group, argue that further use of comparative studies provides patients with additional information necessary to make the best treatment decisions.

Other government offices have weighed in on the practice. Earlier this year the Agency for Healthcare Research and Quality began an initiative to determine the best treatments for a variety of health threats using comparative studies. (http://www.fdanews.com/did/5_129/)

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 13Sep

    Trial Master File Inspection Readiness: From Chaos to Calm

  • 14Sep

    Omnichannel Engagement: Are You Digitally Ready?

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Guardant Health Receives FDA Approval for Guardant360 CDx Liquid Biopsy Test

  • Genentech Inks Licensing Deal With Jemincare Over Androgen Receptor Degrader

  • FDA Clears Thermo Fisher Scientific’s Wheat and Sesame Allergy Tests

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing